Similar Posts
Stablecoins and White-Label Platforms Reshape Institutional Payments, With B2BINPAY Expanding Its Stack
Exness Broker Review 2025: Regulation, Platforms & Trading Conditions Explained | Finance Magnates Exness Broker Review 2025: Regulation, Platforms & Trading Conditions Explained | Finance Magnates Exness Broker Review 2025: Regulation, Platforms & Trading Conditions Explained | Finance Magnates Exness Broker Review 2025: Regulation, Platforms & Trading Conditions Explained | Finance Magnates In this video,…
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KYTX
NEW YORK, Dec. 29, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to the Kyverna’s initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline. SO…
After Memecoins, Trump Shifts Focus to Fintech with Truth.Fi Launch
The media and technology firm associated with US President Donald Trump is making a significant leap into the financial services and FinTech sector with the launch of its new brand, Truth.Fi. The move comes as Trump’s impact in the cryptocurrency space seems to have cooled off. However, the announcement has already sparked a positive market…
CAB Payments Rejects Takeover Approach from StoneX | LeapRate | Online Trading Industry News, Broker Intelligence & Fintech Analysis
CAB Payments has rejected a possible cash offer from StoneX Group Inc., stating that the proposal “significantly undervalues” the business and its medium-term prospects. The company received the unsolicited, non-binding proposal on 15 March, with StoneX indicating a possible offer price of 95 pence per share. CAB Payments’ Independent Board, together with its advisers, carried…
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update. Recent Highlights…
